|
| |
Immucor, Inc. (NASDAQ: BLUD) is a leading supplier of diagnostic reagents and automated instrumentation to ensure the safety of blood transfusions |
| |
Kairos Partners, an 11.6% Immucor shareholder, launched a proxy contest to replace Immucor's board of directors with an alternative slate of directors |
| |
TM Capital Corp. served as advisor to Immucor in its successful effort to defeat the dissident slate and re-elect Immucor's existing directors |
|
|
